NUMA1 and cancer: Many urine-based biomarkers such as nuclear matrix protein 22 (NMP22), bladder tumor antigen (BTA) and cytokeratin are still in the progression of continuous development during the past decades, but no one is ideal and cannot be recommended for large-scale cancer screening [3].